Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
The agreement gives Genentech worldwide rights outside South Korea and includes $190 million upfront, with total payments potentially reaching $2.3 billion.
7 Articles
7 Articles
Hanmi Pharm signs $2.3 bil. licensing deal with Roche's Genentech for obesity drug candidate
Hanmi Pharm, a Korean pharmaceutical company, said Monday it has signed a 3.2 trillion-won ($2.3 billion) licensing deal with Genentech, a U.S.-based member of the Roche Group, for an obesity drug candidate designed to reduce body fat while preserving and increasing muscle mass. Hanmi Pharm has signed an exclusive licensing agreement with Genentech for the development, manufacturing and commercialization of its novel metabolic treatment candidat…
(Seoul = Yonhap News) Reporter Park Sang-hyun = Hanmi Pharmaceutical [128940] and Genentech, a subsidiary of Roche Group, [developed] the candidate substance 'HM17...' for the treatment of metabolic diseases such as obesity and type 2 diabetes.
PR Newswire
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
/PRNewswire/ -- Hanmi Pharm announced today that it has entered into an exclusive licensing agreement with Genentech, a member of the Roche Group, for the...
Hanmi Pharmaceutical is exporting the technology for a next-generation obesity drug candidate that reduces body weight while increasing muscle mass to the global pharmaceutical company Genentech. Hanmi Pharmaceutical disclosed on the 24th that it has signed a technology transfer agreement with Genentech of the United States for the long-acting UCN2 analog ‘HM17321 (LA-UCN2)’. The total value of the contract is $2.305 billion (approximately 3.189…
Coverage Details
Bias Distribution
- 57% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
